Preparation for treating animals with anti-inflammatory and antibacterial actions

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science. The preparation contains pumpkin sludge 84-86%, walnut concentrate 10-12%, the preparation Metrosept 2-3%, emulsifier T2 1-2%.

EFFECT: preparation is safe for animals, effective in treating inflammatory processes and wound surfaces, possesses prolonged action.

4 tbl, 1 ex

 

The invention relates to veterinary medicine, in particular drugs for the treatment of inflammatory processes and wound surfaces.

Improving wound healing is a complex task veterinary practice. The increase in the number of complications, dissatisfaction with the results of treatment in many cases testify to the relevance of the treatment of tissue damage from the violation of their integrity.

Due to the high level of inflammatory diseases, which in most cases become chronic, leading to increased treatment time, the question about the creation of new effective anti-inflammatory and antibacterial drugs for topical use, especially with components of natural origin, having biological activity.

The main goals of treatment of wounds in the first phase of wound healing is the suppression of the infection, the local normalization of homeostasis, activation rejection of necrotic tissue, adsorption of toxic separated wounds (products of microbial and tissue decay) and the relief of pain. In the treatment of wounds in the granulation phase (phase 2) requires a reliable protection of granulation tissue from infection and stimulate its growth, providing conditions for optimal local reactions and metabolic processes in the tissues.

Delay involutional% is Sov (subinvolution) in genitals accompanied by the development of deep histomorphologically changes affects reproductive ability and often leading to infertility in cows. In the development of acute postpartum subinvolution is the intoxication of the body of the animal, greatly disturbed contractile function and retraction of the muscle fibers of the uterus. This creates favorable conditions for penetration through the open cervix into the uterus potentially pathogenic and pathogenic micro-organisms, their multiplication, resulting in subinvolution of the uterus may be complicated by purulent-catarrhal or purulent endometritis. According to numerous authors from diseases of the reproductive organs of cows largest percentage falls in acute puerperal endometritis

Well-known drug for the treatment of skin diseases dermatitis in animals, which is a waste of processing oilseeds mustard (BMF) and is a complex mixture of fats, proteins, carbohydrates, vitamins and antiseptics - allyl mustard oil, inherent oilseeds mustard. The proposed drug is effective, accessible and relatively cheap. (Patent RF №2111781, publ. 27.05.1998).

Known product containing ammonia, dimexide, the BMF from the production of oil from pumpkin seeds and the media type Aerosil-380 in the following ratio, wt.%: 30%solution of Dimexidum 4-5; 0.5%solution of ammonia (ammonia is Peart) 2-4; media Aerosil-380 2-5; BMF - the rest. (Patent RF №2170085, publ. 10.07.2001).

Well-known medication for the treatment of endometritis in cows containing thelan, trichopol, salicylic acid, extract of ergot - arguin, Aerosil and BMF from the production of oil from pumpkin seeds in the following ratio of all the original components, wt.%: thelan - 1,0-2,0; trichopol - 1,0-3,0; ergotan - 1,0-3,0; salicylic acid - 1,0-3,0; emulsifier Aerosil-380 - 2,0-3,0; BMF pumpkin - up to 100%. (Patent RF №2181282, publ. 20.04.2002).

Well-known medication for the treatment of endometritis in cows that contains the BMF pumpkin, Dimexidum, arguin and emulsifier in the following ratio, wt.%: ergotan of 0.01-0.03, Dimexidum 30% aqueous solution of 5.0-10.0, emulsifier ("Aerosil-380") of 2.0 to 3.0, the BMF pumpkin to 100%. (Patent RF №2178295, publ. 20.01.2002).

Known drug "metrosat", which refers to veterinary pharmacology, namely preparations for the treatment of gynecological diseases in cows. Preparation - "metrosat" includes the following components, wt.%: dioxidine - 0,90-1,05, gelatin - 12,88-17,20, glycerin - 49,55-51,33, distilled water - the rest. The drug is used in veterinary practice for the treatment and prevention of inflammation of the uterus of the cow after complicated and pathological childbirth in acute postpartum, catarrhal, pneumatically endometritis, after manual separation of the placenta, uterine prolapse, to the sareva section, when metritis varying severity of the inflammatory process. (Patent RF №1772917, publ. 20.03.1995).

Well-known medication for the treatment of endometritis in cows containing extract of walnuts milky-wax ripeness medical Dimexidum, mustard pumpkin BMF and emulsifier Aerosil-380 in the following ratio, wt.%: extract of walnuts milky-wax ripeness medical Dimexidum 12,0-15,0; emulsifier Aerosil-380 2.0 to 3.0; the BMF mustard pumpkin to 100.0. (Patent RF №2295966, publ. 27.03.2007). This drug is used as a prototype.

Task - the creation of a drug for treatment of inflammatory processes and wound surfaces with natural ingredients with biological activity.

The technical result from the use of this drug is the possibility of treating inflammatory processes and wound surfaces with prolonged action of anti-inflammatory and antibacterial effects, with maximum efficiency of biologically active substances.

The technical result is achieved by creating a drug for the treatment of animals with anti-inflammatory and antibacterial actions, including activetestsuite, biologically active, and structure-forming substances, however, as active substances, use the BMF pumpkin and medicines is Metrosat, as a biologically active substance using a concentrated extract of walnut, as structure-forming substances are used emulsifier T2 in the following ratio, wt.%:

The BMF pumpkin - 84-86

Concentrate walnut - 10-12

Drug Metrosat - 2-3

Emulsifier T2 - 1-2.

Activetestsuite, biologically active, and structure-forming substances included in the composition of the proposed drug, are selected in such a way that their combination in the specified ratio provides maximum anti-inflammatory and antibacterial effect with simultaneous maximum efficiency of biologically active substances.

The BMF pumpkin is a waste of production upon receipt of pumpkin oil. Composition has a complex set of biologically active substances: Tocopherols, carotenoids, phosphatides, amino acids, fatty acids and other, the combined effect of which has a positive effect on the endocrine system, stimulating the activity of the reproductive organs, acting as a highly active biostimulant. The BMF, as the main component of the proposed drug, provides extension (prolongation) of the validity period included in the preparation of biologically active substances - concentrated extract Greck the th walnut milky-wax ripeness and drug Metrosat. Pumpkin BMF obtained in the production of pumpkin oil has the following chemical and amino acid composition. The data are shown in table 1 and table 2

The chemical composition of the BMF pumpkin, %

Table 1
IndexIn air-dry substanceIn the absolutely dry substance
Moisture1,87-
Nitrogen4,29of 4.38
Protein26,827,33
Fat50,4851,49
Fiber10,5910,33
Calcium0,240,24
Factor0,630,63
Potassium0,520,53
Sodium1,40 1,43
Sugar5,045,14
Starch1,01,0

The amino acid composition of BMF pumpkin, 1 mg/g

Table 2
IndexIn air-dry substance
Lysine17,52
Histidine10,15
Arginine8,77
Aspartic acid15,11
Threonine6,45
Spin13,52
Glutamic acid35,6
Proline3,76
Glycine17,37
Alanine10,55
Valine15,02
Methionine2,77
Isoleucine8,12
Leucine17,63
Tyrosine11,59
Phenylalanine16,90

In appearance the BMF is likemetoprolol mass of green-yellow color with the smell of pumpkin seeds.

Concentrated extract of walnut milky-wax ripeness - one stripped off extract walnut milky-wax ripeness. Physico-chemical composition of the obtained concentrated extract are shown in table 3.

Table 3
The name of the component substancesMass fraction mg
Esters ellagic and Gallic acids800,0
Flavonoids60,0
Carotenoids20,0
Ascorbate800,0
Fitosmoly600,0
Nathanon250,0
Calcium15,0
Magnesiumto 12.0
Iron0,3
Cobalt4.0 µg %
Wax200,0
Sugar1200,0
Potassium600,0
Phosphorus400,0
Zinc4,4
Iodine0,50
Manganese0,15
Sulfur1,2
Vitamins: B10.3 mg %
B21.0 mg %
RR500.0 mg %
0.4 mg %
Organic acids:
lemon1,2
Apple1,8
OPANA 0,4
Ethanol60000,0
Cellular water32800,0

From the data in table 3 shows that the concentrated extract of walnut is a biologically active product. The presence of ellagic and Gallic acids contribute to the protection of erythrocytes from hemolysis and provide a stabilizing effect.

Drug Metrosat is an antibacterial drug, a derivative of di-N-oxide finokalia, a wide spectrum of action. Bactericidal action. Active against gram-positive and gram-negative pathogenic and conditionally-pathogenic aerobic bacteria and anaerobic microorganisms: Staphylococcus spp., Streptococcus spp., Escherichia spp., Salmonella spp., Proteus vulgaris, Pseudomonas aeruginosa, Clostridium perfingens. Activity dioksidina increases in anaerobic conditions. Dioxidine selectively inhibits DNA synthesis in microbial cell without affecting the synthesis of RNA and protein. Causes structural changes in the cell wall and in the structure nucleid bacteria, inhibits the activity of the pathogenic factors - extracellular bacterial nucleases, coagulase, α-toxin. Dioxidine active against some bacteria that are resistant to antibiotics and sulfonamides.

The emulsifier is 2 provides the possibility of dosage forms of high quality. Allows you to achieve a homogeneous distribution of drugs. Has a pronounced effect on the rate of release of active substances, which leads to prolonged absorption rate of these substances in animal tissues.

To produce a concentrated extract use nuts milk ripeness, which is filled with ethyl alcohol, then extract insist filtered. Remove ethyl alcohol.

The drug is prepared as follows. To prepare 10 kg of the drug weighed the BMF pumpkin - 8500 g, concentrated extract of walnut - 1100 g drug Metrosat - 250 g, emulsifier T2 - 150 g

Drug Metrosat prepared according to known techniques. To get it in the amount of 250 g give the following number of components: 2,42 g dioksidina, 37,62 g of gelatin; 126,2 g glycerol and 83,75 g of distilled water.

When heated to 60°C. add in the mass-weighed the BMF pumpkin, concentrated extract of walnut and emulsifier T2. The resulting mixture was placed in a mixer and mix until a homogeneous mass. Stand 2 hours at room temperature to a better distribution of the components and again mix. Packed in glass jars.

The drug is a mass of brown-green color with specifically the smell. Is stable for 18 months with proper storage in a dark and cool place.

Study of the effect of the proposed drug on the processes of wound healing were performed on sheep, which in the right hypochondrium did non-sterile skin incision and muscle size 804 mm2and the wound surface is not processed until then, until there was an inflammatory reaction with signs of wound infection. Treating the injury claimed by the drug carry out 1 time per day during the whole observation, however take into account the size of the wound, which was 4 days later - 732 mm2(56.5%); after 7 days - 368 mm2(78,1%); in 10 days - 186 mm2(89%). The wound surface in this case was filled with migrating leukocytes, lymphocytes. The presence of adhesions and cell elements usually regarded as necessary conditions preceding the regeneration of blood vessels and nerve endings. A final and lasting splicing occurred 13 days.

For the treatment of endometritis in cows the drug is administered intrauterine based 85-100 cm3using a syringe Jean, which is connected with ebony catheter. Depending on the condition of the inflammatory process, the drug is administered with an interval of 24-48 hours.

Therapeutic activity of the claimed preparation was examined in the experimental group of 75 cows. After the introduction of the prep the ATA this group of cows calving took place independently, without surgical intervention. Results in comparison with the prototype are given in table 4.

Table 4
Group tummy
data
The number of animalsThe effectiveness of the treatment and prevention of endometritisWere fertilized
goals%goals%
Experienced757397,37194,6
Proto-
type
838096,47792,8%

The inventive product is harmless to animals and has the possibility of treating inflammatory processes and wound surfaces with prolonged action of anti-inflammatory and antibacterial effects, with maximum efficiency of biologically active substances.

The drug for treatment of animals with protivovospalitel the grave and antibacterial action, including activetestsuite, biologically active, and structure-forming substances, characterized in that the quality of active substances, use the BMF pumpkin and drug Metrosat, as a biologically active substance using a concentrated extract of walnut, as structure-forming substances are used emulsifier T2 in the following ratio, wt.%:

The BMF pumpkin84-86
Concentrate walnut10-12
Drug Metrosat2-3
Emulsifier T21-2



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutics and medicine and concerns a pharmaceutical composition for treating and preventing preexcitation syndrome (WPW-syndrome) containing 9-diethylaminoethyl-2-tert-butyl-imidazo[1,2-a] benzimidazole dihydrochloride of formula I as an agent.

EFFECT: composition shows high efficacy.

6 cl, 6 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: present invention refers to medicine and describes a method for preparing a tablet exhibiting antihypertensive activity containing a) an active substance containing valsartan 80 or 160 mg or its pharmaceutically acceptable salt, and hydrochlorothiazide (HCTZ) 12.5 or 25 mg; b) pharmaceutical acceptable additives suitable for preparing tablets by compression wherein said method involves the stages, I) grinding of the active substance which contains said valsartan and said hydrochlorothiazide, and pharmaceutically acceptable additives; II) compression of a mixture of the grinded active substance and additives with making a comprimate with said compression for making the comprimate requires compaction of the dry mixture of the grinded ingredients; III) transformation of the comprimate into a granulate having a particle size distribution 9 to 340 micron; and IV) compression of the granulate with preparing the tablet.

EFFECT: method provides preparing the tablet possessing intensified antihypertensive activity.

4 cl, 3 ex

FIELD: medicine.

SUBSTANCE: studying of mechanisms of correction and prevention of developing hyperhomocytein-induced nitrogen oxide deficiency in a body in experiment is ensured simulating nitrogen oxide deficiency in a laboratory animal by the intragastric introduction of methionine 3 g/kg daily within 7 days. A degree of developing deficiency is evaluated by the relation of endothelium-independent and endothelium-dependent vasodilation (EDV and EIDV). Nitrogen oxide deficiency is corrected by the intragastric introduction of L-norvaline 10 mg/kg 1 hour after the introduction of methionine for 7 days as well.

EFFECT: effective prevention of developing nitrogen oxide deficiency that proves to be true by the varying relation of the areas of blood pressure recovery accompanying endothelium-independent and endothelium-dependent vasodilation.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: studying of mechanisms of correction and prevention of developing hyperhomocytein-induced nitrogen oxide deficiency in a body in experiment is ensured simulating nitrogen oxide deficiency in a laboratory animal by the intragastric introduction of methionine 3 g/kg daily within 7 days. A degree of developing deficiency is evaluated by the relation of endothelium-independent and endothelium-dependent vasodilation (EDV and EIDV). Nitrogen oxide deficiency is corrected by the intragastric introduction of L-norvaline 10 mg/kg 1 hour after the introduction of methionine for 7 days as well.

EFFECT: effective prevention of developing nitrogen oxide deficiency that proves to be true by the varying relation of the areas of blood pressure recovery accompanying endothelium-independent and endothelium-dependent vasodilation.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: studying of mechanisms of correction and prevention of developing hyperhomocytein-induced nitrogen oxide deficiency in a body in experiment is ensured simulating nitrogen oxide deficiency in a laboratory animal by the intragastric introduction of methionine 3 g/kg daily within 7 days. A degree of developing deficiency is evaluated by the relation of endothelium-independent and endothelium-dependent vasodilation (EDV and EIDV). Nitrogen oxide deficiency is corrected by the intragastric introduction of L-norvaline 10 mg/kg 1 hour after the introduction of methionine for 7 days as well.

EFFECT: effective prevention of developing nitrogen oxide deficiency that proves to be true by the varying relation of the areas of blood pressure recovery accompanying endothelium-independent and endothelium-dependent vasodilation.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves simulating gestosis in Wistar rats by the daily intraperitoneal introduction of L-nitro-arginine-methyl ester 25 mg/kg for 14th to 20th day of pregnancy. Gestosis is corrected by using the daily intragastric introductions of L-norvaline 10 mg/kg once a day with underlying simulation for 7 days.

EFFECT: method provides manifested correction of placental microcirculation disorder ensured by increasing L-arginine availability for NO synthesis.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to a compound of formula I where: R1 represents a group selected from among -CH2OH, -NH(CO)H while R2 represents a hydrogen atom or R1, together with R2, forms group -NH-C(O)-CH=CH- where the nitrogen atom is bonded to the carbon atom in the phenyl ring whereto R1 is bonded, the carbon atom bonded to the carbon atom in the phenyl ring whereto R2 is bonded; R3a and R3b are independently selected from the group consisting of hydrogen atoms and C1-4alkyl groups; X and Y are independently selected from the group consisting of an ordinary bond and an oxygen atom; n, m and q (each) independently have a value selected from among 0, 1, 2 and 3; p has a value selected from among 1, 2 and 3; R4 and R5 are independently selected from the group consisting of hydrogen atoms, a halogen atoms, C1-4alcoxy, -CONH2, -NHCONH2, -SR7, -SO2R7 where R7 represents C3-4cycloalkyl; R6 is selected from the group consisting of hydrogen atoms, a halogen atoms, C1-4 alkyl and C1-4alcoxy or its pharmaceutically acceptable salt or a stereoisomer thereof. Additionally, the invention relates to a pharmaceutical composition based on the compound with formula I and to a method for β2-adrenergic receptor activity modulation.

EFFECT: produced are new 4-(2-amino-1-hydroxiethyl) phenol derivatives possessing the activity of β2-adrenergic receptor antagonists.

22 cl, 32 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: this invention relates to a compound ether of docosahexanoic acid and an alcohol, its production method and a pharmaceutical composition applied as a medication for prevention and treatment of cardiovascular diseases. The said alcohol is selected from pentanol with formula: and inositol with formula . The compound ether production method consists in transetherification of docosahexanoic acid ethyl ether with one of the said alcohols.

EFFECT: development of a pharmaceutical composition applied as a medication for production for cardiovascular diseases treatment and prevention.

10 cl, 5 tbl, 1 dwg, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: this invention relates to a compound ether of docosahexanoic acid and an alcohol, its production method and a pharmaceutical composition applied as a medication for prevention and treatment of cardiovascular diseases. The said alcohol is selected from pentanol with formula: and inositol with formula . The compound ether production method consists in transetherification of docosahexanoic acid ethyl ether with one of the said alcohols.

EFFECT: development of a pharmaceutical composition applied as a medication for production for cardiovascular diseases treatment and prevention.

10 cl, 5 tbl, 1 dwg, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: this invention relates to a compound ether of docosahexanoic acid and an alcohol, its production method and a pharmaceutical composition applied as a medication for prevention and treatment of cardiovascular diseases. The said alcohol is selected from pentanol with formula: and inositol with formula . The compound ether production method consists in transetherification of docosahexanoic acid ethyl ether with one of the said alcohols.

EFFECT: development of a pharmaceutical composition applied as a medication for production for cardiovascular diseases treatment and prevention.

10 cl, 5 tbl, 1 dwg, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula (I), where R is n-C12H25 or n-C16H33.

EFFECT: compounds of formula having bactericidal and fungicidal properties.

1 cl, 1 dwg, 1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics. A composition contains nanosized silver powder, nanosized aluminium powder and nanosized diamond powder in the following proportions, wt %: nanosized silver powder - 40, aluminium powder -30, nanosized diamond powder -30.

EFFECT: composition shows a combined immunomodulatory and antibacterial effect, low toxicity.

3 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing concentrates of nanodispersions of zerovalent metals such as silver, gold, copper, palladium, platinum and mercury, which have antiseptic properties. Said method involves mixing a solution of a soluble metal salt in a solvent with ammonia to obtain a complex which is then mixed with alkalnolamine to form a solution. The obtained solution is mixed with a solution of a polymer stabiliser to obtain a stabilised metal cation which is then reduced by adding to the solution an organic or inorganic reducing agent to form a stable dispersion of metal nanoparticles. The disclosed method is realised at a defined ratio of components for 10-60 minutes in an air atmosphere at temperature of up to 100°C.

EFFECT: invention is aimed at obtaining metal dispersions with high sedimentation and chemical resistance and high antiseptic power, which are compatible with a physiological NaCl solution; the method also cuts duration of synthesis and considerably simplifies the process, increases efficiency and complete conversion of cationic metal into a zerovalent metal.

38 cl, 3 tbl, 104 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and is applied in surgery, dermatology, obstetrics, gynaecology and otorhinolaryngology for treating pyoinflammatory processes of soft tissues and mucous membranes. An agent contains the following components, mass fractions: as a base - enterosgel (60.0-80.0), as therapeutic components, an antiseptic - 0.05% chlorhexidine bigluconate (20.0-40.0), and a regeneration stimulator - methyluracil (2.0-4.0).

EFFECT: invention provides the therapeutic agent possessing antiseptic, wound-healing and sorption functions.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers in particular to solutions for mouth rinsing. The water based composition possessing antimicrobic activity consists of: a) from 0,001 to 10 % of weight octenidin dihydrochlorid b) from 0,05 to 30 % of weight of not ionic surface-active substance - derivative fat acids, c) from 0,01 to 10 % of weight poliol, chosen from 1,2-propylene glycol, 1,3 propylene glycol, butane-1,4-diol, sorbite (hexa-1,2,3,4,5,6-hexole) and glycerin or their mix, d) from 0,05 to 10 % of weight of fruit acid and-or its salt chosen from lemon acid, dairy acid, apple acid, wine acid, glycogenic acids, fumaric and amber acid or their mix, e) from 0,025 to 10 % of weight of flavour and-or sweetener, chosen from alitam, aspartame, dulcin, neohesperidin DC, stevioside, sucralose, suosane and thaumatinor their mixtures with water - up to 100 %. The composition is applied as a solution for mouth rinsing and controlling S. Aureus and/or E. faecalis resistant to methicillin.

EFFECT: invention provides efficiency of application as the solution for mouth rinsing awhich is characterized by pleasant taste and a small tendency to foaming.

11 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to creation of composition for oral cavity care, which have, at least, two vegetable active ingredients, obtained from plants. Composition for oral cavity care also includes per oral acceptable carrier for introduction of sufficient amount of, at least, two active ingredients in vivo.

EFFECT: vegetable active ingredients ensure to compositions for oral cavity especially efficient antimicrobial (antibacterial, antiviral and/or antifungal antioxidant anti-inflammatory ageing slowing down and/or healing properties.

5 cl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to proctology, and is intended for low-invasive treatment of complete complex pararectal fistulas. Sinus tract is examined, its direction and presence of external and internal holes are determined. Successively, each sinus tract is treated through external hole, with obturation of external hole of untreated sinus tract, as minimum two times, with two-day interval. Treatment is carried out during 40-80 seconds by ultrasonic fluctuations with frequency 20-60 kHz with simultaneous supply of liquid phase. As liquid phase, used is alcohol solution in amount 10-20 ml, depending on sinus tract dimensions, which is supplied at rate 0.25 ml per second. As alcohol solution used is three percent alcohol iodine solution or seventy percent ethyl alcohol.

EFFECT: method is low-invasive, makes it possible to eliminate injury of anatomical structures of anal canal, reduce treatment cost, can be carried out on outpatient basis.

2 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to - physiotherapy. A method involves simultaneous processing of an area containing microorganisms by a photosensitiser and photocatalyst composition. Thereafter they are kept for a period of time required for effective binding of the composition and microorganism cells. Then this area is exposed to optical radiation at wave length related to a maximal photosensitiser and photocatalyst absorption and power density required for composition activation. The photosensitiser is indocyanine green. The photocatalyst is titanium dioxide nanoparticles.

EFFECT: method provides more effective inactivation of pathogenic and opportunistic microorganisms ensured by higher microorganism radiosensitivity.

8 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: invention is referred to medicine, physiotherapy. A method involves simultaneous processing of an area containing microorganisms by a photosensitiser and photocatalyst composition. They are kept for a period of time required for binding of the composition and microorganism cells. Then this area is exposed to optical radiation. An emission wavelength relates to a maximal photosensitiser and photocatalyst absorption and power density required for composition activation. The photosensitiser is methylene blue or/and brilliant green, and the photocatalyst is titanium dioxide nanoparticles.

EFFECT: method provides an effective microorganism inactivation with using the lower concentration of the photosensitiser ensured by simultaneous use of the photocatalyst and the photosensitiser.

9 cl, 3 tbl, 3 dwg

FIELD: medicine.

SUBSTANCE: method for producing biocide consists in Na-form bentonite activation by sodium ions by means of processing with an aqueous solution of sodium chloride followed by chlorine anion removal with washing and filtration of the prepared raw material. Thereafter, the prepared raw material is intercalated by bactericidal metal ions by processing of inorganic salts in aqueous solutions: silver nitrate, copper sulphate, zinc sulphate or nitrate; sodium salts are removed by washing of the biocide product with deionised water; then the product is filtered, dried and grinded to particle size 20-150 nm. The activation and intercalation processes are performed by exposure to ultrasound at frequency 20-50 kHz and intensity 10-100 Wt/cm2, and the purification process of the intercalated product from sodium salts is two-staged: at first, the product is decanted, and then washed in deionised water containing 30 "ppm" - 100 "ppm" of an alkaline metal ion complexing agent of crown-ethers of molecular weight 264 and less.

EFFECT: production of biocide exhibiting fungicidal and bactericidal efficacy and used in preparations, compounds, compositions.

6 cl, 6 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: invention refers to cosmetology and dermatology, and represents a method for preparing a local skin composition, involving: making fish roe available; and preparing a recovered water-soluble fraction of said fish roe differing by the fact that it contains messenger RNA and protein in the amount of 100 to 380 mg/ml where said fraction is prepared by destruction of said fish roe and decontamination by centrifugation of said lysed fish roe; and introducing said recovered water-soluble fraction of said fish roe into the composition of a cream, a gel, a spray, an emulsion, a solid, plastic material or a matrix, an ointment, a powder or a lotion for local application.

EFFECT: invention provides improved cosmetic appearance, activation, improvement or recovery of cells and tissues, preferentially skin, and more preferentially for recovery of aged or injured skin.

8 cl, 12 ex, 9 tbl, 4 dwg

Up!